Membrane transporters in drug development

@article{Giacomini2010MembraneTI,
  title={Membrane transporters in drug development},
  author={Kathleen M. Giacomini and Shiew-Mei Huang and Donald J. Tweedie and Leslie Z. Benet and Kim L. R. Brouwer and Xiao-yan Chu and Amber Dahlin and Raymond Evers and Volker Fischer and Kathleen M. Hillgren and Keith A. Hoffmaster and Toshihisa Ishikawa and Dietrich Keppler and Richard B. Kim and Caroline A. Lee and Mikko Niemi and Joseph W. Polli and Yuichi Sugiyama and Peter W. Swaan and Joseph A. Ware and Stephen H. Wright and Sook Wah Yee and Maciej J. Zamek-Gliszczynski and Lei Zhang},
  journal={Nature Reviews Drug Discovery},
  year={2010},
  volume={9},
  pages={215-236}
}
Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs. This presents several key questions for drug development, including which transporters are clinically important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters. In addition, what criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if needed. In this article… 
Transporter biology in drug approval: regulatory aspects.
Role of Transporters in Drug Development
TLDR
The authors conclude that the results from transporter-related postmarketing requirement/postmarketing commitment studies are important for dose optimization and have been used to revise drug product labeling, and a critical evaluation of the strength and limitation of each prediction criterion may support efforts toward development of a harmonized decision criterion and facilitate global drug development.
Evaluation of transporters in drug development: Current status and contemporary issues☆
Role of transporters in drug disposition and drug-drug interactions
Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?
TLDR
This review examines key transporters that are important to the absorption, distribution, and excretion of a large number of drugs in clinical use and provides the assessment of the potential impact of known polymorphisms in such transporter and discusses whether there is sufficient evidence to incorporate these polymorphism in the drug development process.
Relevance of Transporters in Clinical Studies
It has become clear that drug disposition is not just a result of passive diffusion and metabolizing enzymes. Numerous transporters were identified in recent years to be involved in the absorption,
Drug transporters in drug efficacy and toxicity.
TLDR
Transporters of the solute carrier and ATP-binding cassette superfamilies are reviewed to outline how understanding the expression, function, and genetic variation in such drug transporters will result in better strategies for optimal drug design and tissue targeting as well as reduce the risk for drug-drug interactions and adverse drug responses.
Drug transporters in drug discovery and development
TLDR
The strategic localization of drug transporters regulates tissue-specific concentrations for many substrate drugs, however, the organ-specific disposition of drugs is not accurately determined by the concentrations clinically measured in plasma.
In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery
TLDR
This article provides an overview of different approaches to evaluate the drug transporters involved in intestinal absorption, hepatic and renal clearance, and brain penetration and discusses the challenges and gaps in understanding the clinical relevance of drugtransporters.
Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics
TLDR
An overview of the current knowledge on human membrane transporters in pediatric drug disposition and effect is presented and existing pharmacokinetic and pharmacogenetic data on membrane substrate drugs frequently used in children are presented and related, where possible, to existing ex vivo data, providing a basis for developmental patterns for individual human membranetransporters.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 249 REFERENCES
A regulatory viewpoint on transporter-based drug interactions
TLDR
A regulatory viewpoint on transporters and their potential role in drug–drug interactions is provided and criteria that may warrant conduct of in vivo P-gp-mediated drug interaction studies based on in vitro assessment are explained.
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
TLDR
This review seeks to discuss the influence intestinal and hepatic drug transporters have on pharmacokinetic parameters, including bioavailability, exposure, clearance, volume of distribution, and half-life, for orally dosed drugs.
Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs.
TLDR
Some examples showing the relationship between haplotypes in transporters and pharmacokinetics and pharmacological effects of drugs are introduced and how to predict the effect of functional changes in drugtransporters caused by genetic polymorphisms on the pharmacokinetic of drugs from in vitro data is discussed.
Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs.
TLDR
Among the large number of transporters, cephalosporins and probenecid have the potential to produce clinically relevant OAT-mediated drug-drug interactions, whereas cyclosporin A and rifampicin may trigger OATP-mediated ones.
Drugdrug interactions involving membrane transporters in the human kidney
TLDR
This review summarises the latest progress in molecular identification and functional characterisation of major drug transporters in the human kidney and focuses on relating cloned renal drug Transporters to clinically observed drugdrug interactions.
Scientific perspectives on drug transporters and their role in drug interactions.
TLDR
The potential role that drug transporters may play in drug-drug interactions and what information may be needed during drug development and new drug application (NDA) submissions to address potential drug interactions mediated by transporter are focused on.
P-glycoprotein recognition of substrates and circumvention through rational drug design.
TLDR
The understanding of how P-gp recognizes and pumps compounds as substrates is discussed and cases where structural changes were made in a chemical scaffold to circumvent the effects of P- gp interactions are described.
Transporters as a determinant of drug clearance and tissue distribution.
  • Y. Shitara, T. Horie, Y. Sugiyama
  • Biology, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2006
...
1
2
3
4
5
...